Evidence map›Paper›PMID 42347613›Full record

ArticleVaccines2026

Development of High-Throughput Serum Bactericidal Assays for

Peter Goldstein, Tania Gensale, Shannon Harris, Tina M Green, Stephanie Noviello, Keith Rubin, Camille Locht, Breeze Cavell, Andrew Gorringe, Luc Gagnon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Peter GoldsteinILiAD Biotechnologies, Inc., Weston, FL 33331, USA.
Tania GensaleIQVIA Laboratories, Laval, QC H7V 3S8, Canada.
Shannon HarrisILiAD Biotechnologies, Inc., Weston, FL 33331, USA.ORCID 0000-0002-9354-0748
Tina M GreenILiAD Biotechnologies, Inc., Weston, FL 33331, USA.
Stephanie NovielloILiAD Biotechnologies, Inc., Weston, FL 33331, USA.
Keith RubinILiAD Biotechnologies, Inc., Weston, FL 33331, USA.
Camille LochtCNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre for Infection and Immunity of Lille, University of Lille, F-59000 Lille, France.ORCID 0000-0001-7295-7336
Breeze CavellUK Health Security Agency, Porton Down SP4 0JG, UK.
Andrew GorringeUK Health Security Agency, Porton Down SP4 0JG, UK.ORCID 0000-0003-2193-7954
Luc GagnonIQVIA Laboratories, Laval, QC H7V 3S8, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesPertussis, caused by

methodsAssay accuracy, precision, linearity, range and robustness of the SBAs against pertactin-positive and pertactin-negative

resultsInter- and intra-assay variability of both assays had coefficients of variation for repeatability < 20% and for intermediate precision of <30%. The assays measured titers ranging from ~8 to ~20,000 and showed high linearity (R

conclusionsHigh-throughput SBAs were developed and qualified against pertactin-positive and pertactin-negative

Indexed as

bactericidal titersBPZE1complement-mediatedpertactinpertussisSBAwhooping cough

Identifiers

PMID42347613
PMCPMC13307608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.